MAGNAIR Device for COPD

Features of the MAGNAIR™ Nebulizer System

The first and only nebulized LAMA, in a closed-system device featuring eFlow® technology1,2*

LONHALA MAGNAIR COPD Device is portable

LONHALA MAGNAIR COPD Device is portable

Portable

Small, light, and compact design allows it to fit in a discreet carrying bag3

  • Handset is 2.4 x 4.7 inches
  • Controller is 1.6 x 4.6 inches
  • MAGNAIR weighs 10.2 ounces (including batteries)

LONHALA MAGNAIR COPD Device provides audiovisual feedback

LONHALA MAGNAIR COPD Device provides audiovisual feedback

Audiovisual feedback mechanisms

Patients will hear 2 beeps and the green LED light will turn off when the device has completed its administration cycle3

LONHALA MAGNAIR COPD Device has a laser-drilled aerosol head

LONHALA MAGNAIR COPD Device has a laser-drilled aerosol head

Laser-drilled aerosol head

Designed only for use with the MAGNAIR Nebulizer System1

The MAGNAIR aerosol head features a vibrating, perforated membrane with laser-drilled holes that is designed to deliver consistently sized particles at 3.7 µm MMAD with proper assembly and cleaning.2-4*

LONHALA MAGNAIR COPD Device and regular tidal breathing

LONHALA MAGNAIR COPD Device and regular tidal breathing

Regular tidal breathing

Patients breathe naturally through the mouthpiece when taking treatment1,3

Patients should be instructed to:

  • Not cover the blue flap with their lips
  • Breathe through the mouthpiece for the duration of the administration period
  • Not inject or swallow the LONHALA solution

LONHALA MAGNAIR COPD Device has a 2-3 minute administration time

LONHALA MAGNAIR COPD Device has a 2-3 minute administration time

2-3 minute administration

Administration takes 2-3 minutes twice daily, with proper assembly and cleaning. Improper cleaning and maintenance may increase administration time.3

It is important for patients to understand how to correctly administer LONHALA vials using MAGNAIR. Instruct patients that LONHALA vials should only be administered via MAGNAIR, and MAGNAIR should not be used for administering other medications.

LONHALA MAGNAIR COPD Device features virtually silent administration

LONHALA MAGNAIR COPD Device features virtually silent administration

Virtually silent administration

Allows patients to take medication without noticeable noise2,5

LONHALA MAGNAIR COPD Device can be battery operated

LONHALA MAGNAIR COPD Device can be battery operated

Battery operated

Can be used with AA batteries or an AC adapter3

Patients should be instructed to carry an extra set of batteries with them at all times if they are powering their device with batteries.

LONHALA MAGNAIR COPD Device has visible aerosol mist

LONHALA MAGNAIR COPD Device has visible aerosol mist

Visible aerosol mist

Patients may see some mist escape through the blue flap on the mouthpiece, providing additional visual administration feedback3

LONHALA solution is for oral inhalation only and should not be injected or swallowed. LONHALA vials should only be administered with MAGNAIR.

*The eFlow Closed System is part of PARI's electronic nebulizer platform. It features a vibrating, perforated membrane with laser-drilled holes that is designed to deliver consistently sized particles and to nebulize the solution for administration.2,4

COPD=chronic obstructive pulmonary disease; LAMA=long-acting muscarinic antagonist; MMAD=mass median aerodynamic diameter.


References:
1.
LONHALA™ MAGNAIR™ (glycopyrrolate) Inhalation Solution [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc.
2. Pham S, Ferguson GT, Kerwin E, Goodin T, Wheeler A, Bauer A. In vitro characterization of the eFlow closed system nebulizer with glycopyrrolate inhalation solution. [published online ahead of print Nov 10, 2017]. J Aerosol Med Pulm Drug Deliv. Doi:10. 1089/jamp.2017.1384.
3. LONHALA™ MAGNAIR™ (glycopyrrolate) Inhalation Solution [instructions for use]. Marlborough, MA: Sunovion Pharmaceuticals Inc.
4. PARI eFlow® Technology Device Comparison Chart. Foundation Care Pharmacy. https://www.foundcare.com/wp-content/uploads/2016/08/fnc_device_chart.pdf. Accessed March 6, 2018.
5. Data on file. eLete Loudness measurement. Test Report 4669, 2017. PARI Pharma GmbH.

Important Safety Information & Indication

Important Safety Information
 

LONHALA MAGNAIR is contraindicated in patients with a hypersensitivity to glycopyrrolate or to any of the ingredients.

LONHALA MAGNAIR should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

As with other inhaled medicines, LONHALA MAGNAIR can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with LONHALA MAGNAIR, it should be treated immediately with an inhaled, short-acting bronchodilator; LONHALA MAGNAIR should be discontinued immediately and alternative therapy instituted.

Immediate hypersensitivity reactions have been reported with LONHALA MAGNAIR. If signs occur, discontinue LONHALA MAGNAIR immediately and institute alternative therapy.

LONHALA MAGNAIR should be used with caution in patients with narrow-angle glaucoma and in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema) and of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Patients should be instructed to consult a physician immediately should any of these signs or symptoms develop.

The most common adverse events reported in ≥2% of patients taking LONHALA MAGNAIR, and occurring more frequently than in patients taking placebo, were dyspnea (4.9% vs 3.0%) and urinary tract infection (2.1% vs 1.4%).

LONHALA solution is for oral inhalation only and should not be injected or swallowed. LONHALA vials should only be administered with MAGNAIR.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional information, please see full Prescribing Information and Patient Information for LONHALA MAGNAIR at www.sunovionprofile.com/lonhala-magnair.

Indication
 

LONHALA™ MAGNAIR™ (glycopyrrolate) is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.